Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 58Breast Neoplasms 14Polycystic Ovary Syndrome 9Infertility 7Ovarian Hyperstimulation Syndrome 3Neoplasms 3Neoplasm Metastasis 3Lymphoma 3Sarcoma, Ewing 2Sarcoma 2Prostate Adenocarcinoma 2Osteosarcoma 2Uterine Anomalies 1The Neoadjuvant Therapy 1Sleep Wake Disorders 1Salpingitis 1Salivary Gland Neoplasms 1Primary Ovarian Insufficiency 1Pregnancy, Ectopic 1Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel 1Myofibroma 1Metabolic Syndrome 1Leiomyoma 1Infertility, Female 1Hypogonadism 1Hodgkin Disease 1Hematopoietic and Lymphatic System Neoplasm 1Helping Behavior 1Fatty Liver 1Fatigue 1

Interventions

luprolide acetate gel depot 1enzalutamide 1Triptorelin Pamoate 1Radiosurgery 1Leuprolide 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castration-resistant Prostate Cancer Patients with Oligometastases × Triptorelin Pamoate × Clear all
NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡